Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Artiva Biotherapeutics, Inc. - Common Stock (NQ:ARTV)

3.570 -0.190 (-5.05%)
Streaming Delayed Price Updated: 12:49 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Artiva Biotherapeutics, Inc. - Common Stock

News headline image
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Dr. Banerjee’s appointment culminates Artiva’s efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy 
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.